Oclorus™Spermidine Supplement
  • Home
  • Fisetin
  • Dasatinib-Quercetin
  • Navitoclax (ABT-263)
  • UBX1325
  • More
    • Home
    • Fisetin
    • Dasatinib-Quercetin
    • Navitoclax (ABT-263)
    • UBX1325
Oclorus™Spermidine Supplement
  • Home
  • Fisetin
  • Dasatinib-Quercetin
  • Navitoclax (ABT-263)
  • UBX1325

D+Q(Dasatinib+Quercetin)–for Research&Bulk Supply

<img src="quercetin.jpg" alt="Mitora™ Quercetin senolytic compound for research use">

Product Overview

Mitora™D+Q is a research-grade senolytic compound combination of Dasatinib and Quercetin, widely used in aging, cellular biology, and preclinical studies. This synergistic formulation is designed to selectively target and eliminate senescent cells, providing reproducible results for in vitro and experimental research. 

Mitora™D+Q (Dasatinib + Quercetin) – High-Purity Senolytic Compound for Research & Bulk Supply

Technical Specifications

  • Components: Dasatinib + Quercetin
     
  • CAS Numbers: Dasatinib–302962-49-8, Quercetin–117-39-5
     
  • Appearance: Yellow to pale-yellow crystalline powder
     
  • Purity: ≥99% for each component
     
  • Storage: Store in a cool, dry place, protected from light

Key Features

  • High Purity & Quality: Both Dasatinib and Quercetin are ≥99% pure, ensuring reliable and reproducible results.
     
  • Research-Grade Compound: Ideal for laboratory applications, cellular senescence studies, and aging research.
     
  • Bulk Supply: Flexible quantities available for B2B distributors, research institutions, and biotech companies.
     
  • Certificate of Analysis (COA): Each batch comes with a COA to verify purity and identity.
     
  • Synergistic Senolytic Action: D+Q combination is a widely studied senolytic regimen in preclinical research.


Copyright©2023 Mitora™

Powered by Mitora™

  • Cardiac glycosides
  • Navitoclax-ABT-263
  • Ouabain–Cardiac Glycoside
  • Piperlongumine
  • 17-DMAG–HSP90 Inhibitor
  • Quality & Technology
  • About Us
  • Terms of Service
  • Privacy Policy
  • FAQ
  • Contact Us
  • Senolytic Compound News
  • Equal Opportunity
  • Legal Disclaimer–Mitora™
  • Health & Safety–Mitora™
  • Accessibility Statement

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept